CSPC Pharmaceutical Group. has filed a patent for the use of mitoxantrone hydrochloride liposome and pegaspargase in the preparation of a drug for treating NK/T-cell lymphoma (NKTCL). The invention aims to improve the curative effect of pegaspargase on NKTCL while minimizing toxic and side effects. The patent also includes a method for administering the drug to patients. GlobalData’s report on CSPC Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CSPC Pharmaceutical Group, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. CSPC Pharmaceutical Group's grant share as of September 2023 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230293454A1) describes the use of mitoxantrone liposome and pegaspargase in the preparation of a drug for treating NK/T-cell lymphoma. The patent claims that this combination can improve the efficacy of pegaspargase for treating this type of lymphoma. The drug can be administered in various forms, including liquid injection, powder for injection, and tablet for injection. The patent also mentions that the drug may include other drugs for treating NK/T-cell lymphoma.
The patent further specifies that the drug is suitable for treating different types of NK/T-cell lymphoma, including treatment-naïve, relapsed, and refractory extranodal NK/T-cell lymphoma, particularly extranodal nasal NK/T-cell lymphoma. The mitoxantrone liposome used in the drug is mitoxantrone hydrochloride liposome. The patent provides dosage information for the drug, stating that the mitoxantrone hydrochloride liposome should contain 0.5 to 5 mg/ml of the active ingredient when used as a liquid injection. The pegaspargase should contain asparaginase in an amount of 1000 to 5000 IU/5 ml when used as a liquid injection.
The patent also describes methods for treating NK/T-cell lymphoma using the drug. The therapeutically effective amount of mitoxantrone hydrochloride liposome is specified as 8 to 30 mg/m2, and the administration cycle is once every 3 weeks. The dosage of pegaspargase is recommended to be 2000 to 2500 IU/m2, administered intramuscularly.
In addition to treating NK/T-cell lymphoma, the patent claims that the drug can also improve the efficacy of pegaspargase for treating extranodal NK/T-cell lymphoma. The mitoxantrone hydrochloride liposome is administered at a dosage of 8-30 mg/m2, once every 3 weeks, and can be administered before, during, or after the administration of pegaspargase.
The patent also provides information about the composition of the mitoxantrone hydrochloride liposome. The particle size of the liposome is about 30 to 80 nm, and it contains the active ingredient mitoxantrone. The lipid bilayer of the liposome includes phospholipids with a phase transition temperature higher than body temperature, such as phosphatidylcholine, hydrogenated soy lecithin, hydrogenated ovolecithin, lecithin bis palmitate, lecithin bis stearate, or any combination thereof.
Overall, this patent describes the use of mitoxantrone liposome and pegaspargase in the preparation of a drug for treating NK/T-cell lymphoma, including different subtypes of the disease. The patent provides dosage information and administration methods for the drug, as well as details about the composition of the mitoxantrone liposome.
To know more about GlobalData’s detailed insights on CSPC Pharmaceutical Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
